Replies to post #198813 on Biotech Values

[kris_kade]

XLRN deal is quite strong indeed. I think some sellers are booking profits from October low of $22+ but stock should rally upon market reversal.

[DewDiligence]

XLRN -4%/AH on phase-2 failure in RCC:

https://finance.yahoo.com/news/acceleron-announces-top-line-results-203000167.html